Hormone replacement therapy and prevention of vertebral fractures: A meta-analysis of randomised trials

BMC Musculoskeletal Disorders

Volumn 2, Issue , 2001, Pages 1-4

  Torgerson, David J ^a   Bell Syer, Sally E M ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL;

ADULT; AGED; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOUBLE BLIND PROCEDURE; FEMALE; FRACTURE REDUCTION; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; VERTEBRA FRACTURE;

EID: 0345183982     PISSN: 14712474     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-2-7     Document Type: Review

References (17)

1. Lufkin EG, Wahner HW, O'Fallon WM, et al: Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117:1-9
2. Windeler J, Lange S: Events per person year - a dubious concept. BMJ 1995, 310:454-456
3. Torgerson DJ, Bell-Syer SEM: Hormone Replacement Therapy and Prevention of Nonvertebral Fractures: A Meta-analysis of Randomized Trials. JAMA 2001, 285:2891-2897
4. Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, Cummings SR: Effects of Hormone Replacement Therapy on Clinical Fractures and Height Loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001, 110:442-450
5. Delmas PD, Confavreux E, Garnero P, Fardellone P, Vernejoul MC, Cormier C, Arce JC JC: A combination of low doses of 17b-Estradiol and Norethisterone Acetate Prevents Bone Loss and Normalizes bone turnover in postmenopausal women. Osteoporosis International 2000, 11:177-187
6. Herrington DM, Reboussin DM, Broshnihan KB, Sharp PC, Shumaker SA, Snyder TE, et al: Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis. N Engl J Med 2000, 343:522-529
7. Mosekilde L, Beck-Nielsen H, Sorensen OH, Nielsen SP, Charles P, et al: Hormonal Replacement Therapy Reduces Forearm Fracture Incidence in Recent Postmenopausal Women: Results of the Danish Osteoporosis Prevention Study. Maturitas 2000, 36:181-193
8. The Writing Group for the PEPI Trial: Effect of Hormone Therapy on Bone Mineral Density. JAMA 1996, 276:1389-1396
9. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al: Alendronate and Estrogen-Progestin in the Long Term Prevention of Bone Loss: Four-Year Results from the early Postmenopausal Intervention Cohort Study. Ann Intern Med 1999, 131:935-942
10. Recker RR, Davies KM, Heaney RP: The Effect of Low-Dose Continuous Estrogen and Progesterone Therapy with Calcium and Vitamin D on Bone in Elderly Women: A Randomized Controlled Trial. Ann Intern Med 1999, 130:897-904
11. Wimalawansa SJ: A Four-Year Randomized Controlled Trial of Hormone Replacement Therapy and Bisphosphonate, Alone or in Combination, in Women with Postmenopausal Osteoporosis. Am J Med 1998, 104:219-226
12. Alexandersen P, Riis BJ, Christiansen C: Monoflurophosphate Combined with Hormone Replacement Therapy Induces a Synergistic Effect on Bone Mass by Dissociating Bone Formation and Resoprtion in Postmenopausal Women: A Randomized Study. J Clin Endocrinol Metab 1999, 84:3013-3020
13. Lindsay R, Hart DM, Forrest C, Baird C: Prevention of Spinal Osteoporosis in Oophorectomised Women. Lancet 1980, ii:1151-1154
14. Gallagher JC, Fowler SE, Detter JR, Sherman SS: Combination Treatment with Estrogen and Calcitriol in the Prevention of Age-Related Bone Loss. J Clin Endocrinol Metab 2001, 86:3618-3628
15. Ishida Y, Soh H, Tsuchida M, Kawahara S, Murata H: Comparison of the Effectiveness of Hormone Replacement Therapy, Bisphosphonate, Calcitonin, Vitamin D and Vitamin K in Postmenopausal Osteoporosis: A One Year Prospective Randomized Controlled Trial. Bone 2001, 28 Supp 1:S224
16. McClung MR, Geusens P, Miller PD, Zipple H, Bensen WG, Roux C, et al: Effect of Risedronate on the Risk of Hip Fracture in Elderly Women. N Engl J Med 2001, 344:333-340
17. Ettinger B, Mitlak BH, Nickelson T, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from 3-year randomised clinical trial. JAMA 1999, 282:637-645